{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"17.51","upperLimit":"NA","value":"22.57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"TTP was measured as the time in months from the first dose of study treatment to the date of the first documented PD as assessed using IMWG criteria. PD required one of the following: increase of ≥ 25% from nadir in: serum M-component (absolute increase ≥ 0.5 g/dL); urine M-component (absolute increase ≥ 200 mg/24 hours); in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase \\> 10 mg/dL); development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dL) attributed solely to plasma cell proliferative disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.","id":"OG000","title":"Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who received at least one dose of study drug during the treatment period.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}